정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2494 | Recruiting | A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells) | COVID-19 | Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen Biological: Low-dose placebo (18-59 years) & Two dose regimen Biological: Low-dose placebo (18-59 years) & Three dose regimen Biological: High-dose placebo (18-59 years) & Two dose regimen Biological: High-dose placebo (18-59 years) & Three dose regimen Biological: Low-dose placebo (60-85 years) & Two dose regimen Biological: Low-dose placebo (60-85 years) & Three dose regimen Biological: High-dose placebo (60-85 years) & Two dose regimen Biological: High-dose placebo (60-85 years) & Three dose regimen |
Phase 2 | Jiangsu Province Centers for Disease Control and Prevention, West China Hospital | NETWORK | 960 | All | 18 Years ~ 85 Years | Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China |
| 2493 | Enrolling by invitation | A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19 | SARS-CoV-2 | Biological: Biological: oral polio vaccine Biological: Comparable Placebo Drug: NA-831 Drug: Comparable Placebo of drug Combination Product: Combination of oral polio vaccine and NA-831 Combination Product: Comparable Placebo of Oral Polio Vaccine and Placebo of drug |
Phase 3 | NeuroActiva, Inc., Biomed Industries, Inc. | INDUSTRY | 3600 | All | 18 Years | Coronavirus Research Institute- Testing Site, Los Angeles, California, United States Coronavirus Research Institute, Orange, California, United States Coronavirus Research Institute-Testing Site, Palo Alto, California, United States Coronavirus Research Testing Site, San Francisco, California, United States Coronavirus Research Institute-Testing Site, Sunnyvale, California, United States Coronavirus Research Institute, Sunnyvale, California, United States Coronavirus Research Institute-Testing Site, Naperville, Illinois, United States Coronavirus Research Institute-Testing Site-, Bronx, New York, United States NeuroActiva-Clinical Research Unit, Auckland, New Zealand NeuroActiva Testing Facility of NeuroActiva (New Zealand) Ltd, Auckland, New Zealand |
| 2492 | Recruiting | A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients | COVID-19 | Drug: GT0918 tablets or placebo | Phase 3 | Suzhou Kintor Pharmaceutical Inc, | INDUSTRY | 724 | Male | 18 Years | Hospital Santa Paula, Sao Paulo, SP, Brazil |
| 2491 | Completed | A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants | COVID-19 | Biological: BNT162b2 Biological: BNT162b2.B.1.351 |
Phase 3 | BioNTech SE, Pfizer | INDUSTRY | 1530 | All | 12 Years ~ 50 Years | Kaiser Permanente Oakland, Oakland, California, United States Clinical Research Consulting, Milford, Connecticut, United States Indago Research & Health Center, Inc, Hialeah, Florida, United States Research Centers of America, Hollywood, Florida, United States Clinical Neuroscience Solutions, Orlando, Florida, United States Clinical Research Atlanta, Stockbridge, Georgia, United States East-West Medical Research Institute, Honolulu, Hawaii, United States Solaris Clinical Research, Meridian, Idaho, United States Kentucky Pediatric/Adult Research, Bardstown, Kentucky, United States Amici Clinical Research LLC, Raritan, New Jersey, United States Accellacare - Wilmington, Wilmington, North Carolina, United States Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States Texas Center for Drug Development, Inc., Houston, Texas, United States Clinical Trials of Texas, Inc., San Antonio, Texas, United States Martin Diagnostic Clinic, Tomball, Texas, United States J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States |
| 2490 | Active, not recruiting | A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects | Covid19 | Drug: LY-CovMab | Phase 1 | Luye Pharma Group Ltd., Shandong Boan Biotechnology Co., Ltd | INDUSTRY | 42 | All | 18 Years ~ 45 Years | The Second Hospital of Anhui Medical University, Hefei, Anhui, China |
| 2489 | Recruiting | A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 | COVID-19 | Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells | Phase 2 | Chongqing Public Health Medical Center, Chongqing Sidemu Biotech, Zhejiang Qixin Biotech | OTHER | 90 | All | 18 Years | Chongqing Public Health Medical Center, Chongqing, China |
| 2488 | Active, not recruiting | A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) | COVID-19 | Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) Other: Placebo |
Phase 2 | Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China, CanSino Biologics Inc., Jiangsu Province Centers for Disease Control and Prevention, Hubei Provincial Center for Disease Control and Prevention, Zhongnan Hospital | OTHER | 508 | All | 18 Years | Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China |
